Clinical trial Recruiting at 1 site Interventional Ages 50 and up Women only

Ablation versus breast-conserving surgery for early hormone receptor–positive breast cancer

Official title: Prospective, Randomized Controlled Study Comparing Cryo-Thermal Ablation With Traditional Breast-Conserving Surgery in HR-Positive, HER2-Negative Early-Stage Breast Cancer

Run by Peking University People's Hospital · NCT07484087 · Data updated 2026-11-12

This trial will test whether a minimally invasive hybrid cryo-thermal ablation works as well as breast-conserving surgery for women aged 50 and older with a single, small ER/PR-positive, HER2-negative early breast cancer.

Quick facts

Study typeInterventional
Ages50 Years and up
SexWomen only
Enrollment264 (estimated)
SponsorPeking University People's Hospital
Academic / other
Drugs / interventionschemotherapy, immunotherapy
Locations1 site (Beijing, Beijing Municipality)
StatusRecruiting
StartedJanuary 1, 2026
Main results expectedDecember 31, 2028
Study endsDecember 31, 2031
Registry record updatedMarch 19, 2026
Trial IDNCT07484087 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are women aged 50 or older with a single, ultrasound-visible invasive ductal carcinoma ≤2 cm, grade 1–2, ER/PR-positive, HER2-negative, and no clinical or radiologic lymph node involvement who agree to randomization.

Probably not a fit

Patients with multifocal disease, extensive intraductal component, skin or muscle invasion, prior treatment for the current cancer, or who are pregnant or breastfeeding are unlikely to benefit from this trial.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, single-center, randomized controlled trial at Peking University People's Hospital that will randomize eligible patients 1:1 to receive hybrid cryo-thermal ablation or standard breast-conserving surgery. Eligible patients are women aged 50 or older with a unifocal invasive ductal carcinoma ≤2 cm, grade 1–2, ER/PR-positive and HER2-negative, and clinically node-negative. The hybrid device combines deep cryoablation and high-intensity heating and is applied under imaging guidance for ultrasound-visible tumors. Clinical and clinicopathological data will be collected to compare outcomes between the two groups.

Why it matters

Potential benefit: If successful, this approach could offer a less invasive treatment that preserves breast appearance while maintaining cancer control.

How similar studies have gone: Ablative techniques such as cryoablation have shown promising results in small studies, but the hybrid cryo-thermal approach is relatively novel and has not been widely compared with surgery in large randomized trials.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* 1.Age ≥50 Years 2.Unifocal disease (single tumor) confirmed by ultrasound, MRI, or mammography. Ultrasound visibility: Essential for precise intraoperative ablation targeting. 3.Pathologically Confirmed Invasive Ductal Carcinoma (IDC)。Diagnostic Method: Core needle biopsy (CNB) confirming IDC.

  4.Histologic Grade: G1 or G2; ER/PR-positive and HER2-negative. 5.TNM stage: IA. Tumor Size: ≤2 cm; Lymph Node Status: Clinically \& radiologically negative (no palpable/imaging-detected axillary involvement).

  6.Written consent for clinical trial participation and acceptance of random assignment

Exclusion Criteria:

* 1.Extensive intraductal component (EIC) suggested by imaging or pathology. 2.Invasion of adjacent skin or muscle. 3.Prior anticancer treatment for the current disease, including but not limited to chemotherapy, endocrine therapy, targeted therapy, or immunotherapy. 5.Refusal to undergo breast-conserving surgery. 6.Pregnancy or lactation. 7.Previous radiotherapy to the affected breast or other contraindications to radiotherapy. 8.Concurrent untreated malignancies or severe systemic diseases, 9.Known allergy, intolerance, or contraindications to cryotherapy (e.g., cryoglobulinemia, implanted electronic devices). 10.Inability to comply with follow-up or refusal of adjuvant therapy. 11.Vulnerable populations, including individuals with neurological disorders, cognitive impairment, or critical illness.

Where it's running

  • Peking University People's Hospital
    Beijing, Beijing Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.